Loading
Life sciences · Journal article
Medicine · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Coronary artery disease (CAD) is a highly prevalent condition that predominantly affects obese individuals and those with metabolic abnormalities. The lipid accumulation product (LAP), combining waist circumference (WC) and triglyceride (TG) measurements, provides a clinically relevant metric for evaluating adipose tissue deposition. However, existing research findings regarding its association with CAD remain inconsistent. Therefore, this study further investigates the relationship between LAP and CAD to elucidate whether the LAP index can serve as a reliable screening tool for identifying individuals at high risk for CAD. Utilizing the National Health and Nutrition Examination Survey 2017–2020 database, we performed logistic regression analysis to investigate the association between LAP and CAD. Receiver operating characteristic (ROC) curve analysis was applied to assess the predictive performance of LAP and other metabolic parameters in relation to CAD. Additionally, subgroup analyses and interaction tests were performed to detect possible effect modifiers and verify the robustness of findings across different population strata. Our study recruited 7860 participants, among whom 499 individuals were diagnosed with CAD. A statistically significant association between LAP and CAD was established through regression analysis (OR: 4.12, 95% CI: 2.06–6.23, P <.001). ROC analysis found that LAP demonstrates moderate-to-good discriminatory power for CAD (AUC: 0.789, 95% CI: 0.773–0.805, P <.001) when compared to other metabolic markers. Notably, a statistically significant elevation in LAP levels is observed among CAD patients when compared to their counterparts without CAD. These results support its integration into clinical protocols as a gatekeeper screening mechanism for primary CAD prevention.